Comparison between Benign and Malignant Primary Bone Tumors-A Histopathological Study of 119 Cases


  • Farah Falah Hasan Department of Pathology, Collage of Medicine, Kerbela University
  • Haider Lateef Mohammed Department of Pathology, Alwasiti Teaching Hospital



This is a prospective study done at Al wasity teaching hospital for reconstructive surgeries in Bagdad in a period from November 2014 to April 2017, using a Total of 119 samples of primary bone tumors which were diagnosed both histopathologically and radiologically. The main objectives of this study was to make a comparison between benign and malignant bone tumors. Immunohistochemical staining was done to confirm the diagnosis of primary malignant bone tumors and the proliferative index of them were carefully evaluated. Out of 119 samples of primary bone tumors used in this study ,100 (84%) were benign and borderline(osteoclastoma) and 19(16%) were malignant, the mean age for benign tumors was lower than the mean age for primary malignant one and both frequently present in the 2nd decade of life, male to female ratio for benign bone tumors was 3\2 and 8.5\1 for primary malignant one, femure was the most common location for benign bone tumors while tibia was the most common bone affected by primary malignant bone tumors. the study also showed that the most common benign bone tumors were osteochondromas(67%) and most common primary malignant bone tumors were osteosarcomas(52.63%),thus this study rise a conclusion that in general, primary bone tumors were mainly benign, occurred predominantly in the second decade of life with a male preponderance


Deng ZL, Sharff KA, Tang N, Song WX, Luo J, Luo Xet al. Regulation of osteogenic differentiation during skeletal development. Front Biosci., 13:2001-21, 2008. DOI:

Kollet O, Dar A, Lapidot T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Ann. Rev Immunol., 25:51-69, 2007. DOI:

Rosenberg AE. Bones. In Kumar V, Abbas AK, Fausto N. Robbins and Cotran. Pathologic basis of disease. 7th ed. Philadelphia: Elsevier saunders: 1273-324, 2005.

Alessandro Franchi .Epidemiology and classification of bone tumors, Clin Cases Miner Bone Metab., 9(2): 92–95, 2012.

Hogendoorn PC, Athanasou NA, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Jurgens H, Paulussen M, Roseman L, Taminiau AH, Whelan J, Vanel D.Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol., 21 (5): 204-213, 2010. DOI:

Rajani R, and Parker Gibbs C. Treatment of Bone Tumors. Surg Pathol Clin., 5(1): 301–318, 2012. DOI:

Zambo I, Veselý K. .WHO classification of tumours of soft tissue and bone 2013: the main changes compared to the 3rd edition]. Cesk Patol., 50(2):64-70, 2014.

Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE: AFIP Atlas of Tumour Pathology; 4th Series, Fascicle 2: Tumors of the Bones and Joints., Washington, 2005.

Vlychou M and Athanasou NA: Radiological and pathological diagnosis of pediatric bone tumors and tumour-like lesions. Pathology. 2008, 40: 196-216. DOI:

Juan Roai: Rosai and Ackerman's Surgical Pathology. 10th edition. Elsevier Mosby’s united-state, 2:2043-2046, 2011.

Costello C.M., and Madewell JE. Radiography in the Initial Diagnosis of Primary Bone Tumors,American Journal of Roentgenology., 200(1): 3-7, 2013. DOI:

Choi Y, Chi G, Yeon L. CD99 immunoreactivity in ependymoma. Appl. Immunohistochem. Mol Morphol., 9:125–129,2001. DOI:

Hasteh F, Lin GY, Weidner N, and Michael CW. The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions Cancer .Cancer Cytopathol, 118:90–6, 2010. DOI:

Niveditha S. R. and Bajaj P. Vimentin expression in breast carcinomas. Indian Journal of Pathology & Microbiology, 46(4):579–584, 2003.

Jason R. Karamchandani, MD, Torsten O. Nielsen, MD, PhD,w Matt van de Rijn, MD, PhD,Robert B..Sox10 and S100 in the Diagnosis of Soft-tissue Neoplasms Appl Immunohistochem Mol Morphol, 20(5):445-450, 2012. DOI:

Effrey Vos EA, Susan L Abbondanzo, Carol L Barekman, JoAnn W Andriko, Markku Miettinen and Nadine S. Aguilera. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Modern Pathology, 18: 693–704, 2005. DOI:

Deau-Fischer B, Pierre Taupin,Vincent Ribrag, Richard Delarue, Jacques Bosq, Marie-Thérèse Rubioeta. Prognostic Significance of New Immunohisto-chemical Markers in Refractory Classical Hodgkin Lymphoma: A Study of 59 Cases 4(7):1-5, 2009. DOI:

Turcotte RE, Giant cell tumor of bone. Orthop Clin North Am., 37(1):35-51, 2006. DOI:

Bamanikar SA, Pradhan M. Pagaro1, Praveen Kaur, Shirish S. Chandanwale, Arvind Bamanikar, Archana C. Buch, Dr. D. Y. Patil. Hospital and Histopatho-logical Study of Primary Bone Tumours and Tumour-Like Lesions in a Medical Teaching Hospital. JKIMSU., 4(2): 46-55, 2015.

Karun Jain, Sunila, R. Ravishankar, -Mruthyunjaya, C. S. Rupakumar, H. B. Gadiyar, and G. V. Manjunath. Bone tumors in a tertiary care hospital of south India: A reviews 117 cases.indian J Med Paediatric Oncol., 32(2): 82–85, 2011. DOI:

Kareem Al zirkan. The Pattern of Primary Malignant Bone Tumors in Nassyriha 76 Thi-Qar health office. Kufa Med. Journal, 13(2): 76-90, 2010.

Shubhi Sharma, Nandita P. Mehta. Histopathological Study of Bone Tumors. IJSR., 4(12):1970-1972, 2015. DOI:

Negash BE, Admasie D, Wamisho BL, Tinsay MW. bone Tumors at Addis Abbas University Ethiopia, Agreement Between Radiological and Histopatho-logical Diagnosis – A 5 year analysis at Black Lion Teaching Hospital, Malawi. Med J, 1:62-5, 2009.




How to Cite

F. F. Hasan and H. L. Mohammed, “Comparison between Benign and Malignant Primary Bone Tumors-A Histopathological Study of 119 Cases”, MJS, vol. 29, no. 2, pp. 74–82, Nov. 2018.



Biological Science